Meirong Xu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.(More)
  • 1